Spelling suggestions: "subject:"agonist"" "subject:"gonist""
1 |
Investigations of derivatives of 14#beta#-amino-7,8-dihydromorphinoneNieland, Nick January 1998 (has links)
No description available.
|
2 |
The #gamma#-aminobutyrate/benzodiazepine receptor from pig brain : Purification and characterizationKirkness, E. F. January 1986 (has links)
No description available.
|
3 |
Studies on dopamine and opioid receptor subtypes : Their interactions in the C.N.SRooney, K. F. January 1987 (has links)
No description available.
|
4 |
Neuronale Modulation der Einfluss von Agonisten und inverser Agonisten auf das Cannabinoidsystem einer hippocampalen Primärkultur /Klink, Oliver, January 2007 (has links)
Hohenheim, Univ., Diss., 2007.
|
5 |
Synthese von nicht-natürlichen Aminosäuren und Aminosäure-Konjugaten : pharmakologisch interessante Bausteine für Peptidmimetika /Kirschbaum, Bettina. January 1996 (has links) (PDF)
Univ., Diss.--Stuttgart, 1996.
|
6 |
Design, parallel synthesis and biological evaluation of agonists for the G-protein coupled human orphan receptor BRS-3Weber, Dirk. January 2003 (has links) (PDF)
München, Techn. Univ., Diss., 2003.
|
7 |
Group I mGlu receptors : desensitization properties and modulation of cerebrocortical glutamate releaseReid, Morag January 2000 (has links)
No description available.
|
8 |
Functional aspects of neuronal nicotinic receptor diversityCovernton, Patrick John O'Neill January 1999 (has links)
No description available.
|
9 |
Initial Flare Symptoms Resulting from Use of LHRH Agonist in Metastatic Prostate Cancer: Systematic Review and Economic EvaluationPoon, Yeesha 03 January 2011 (has links)
Background
LHRH agonists decrease tumour size/activity by suppressing testosterone in prostate cancer; however, initial injection causes testosterone surge that triggers flare symptoms. Anti-androgen given with agonist may reduce/avoid flare symptoms.
When LHRH antagonist/blocker is introduced, testosterone suppression is immediate, but there is uncertainty about significance of flare symptoms without anti-androgen.
Objective
Systematic review compared significance of flare symptoms avoided and cost utility analysis using modelling comparing incremental value of blocker (degarelix) OR agonist (goserelin)+anti-androgen (bicalutamide) VERSUS agonist alone in prostate cancer patients.
Outcome
Incremental cost/QALY of bone pain as flare symptom between treatments
Results
Thirteen studies were reviewed. There was no standard definition for flare symptoms or data on LHRH antagonist versus other treatments on flare. From societal perspective, goserelin+bicalutamide was dominated over goserelin alone and similarly, from public perspective, goserelin+bicalutamide had favourable cost effectiveness profile against goserelin.
Conclusion
With bone pain as clinical endpoint, LHRH agonist+anti-androgen had favourable cost-effectiveness profile compared to goserelin.
|
10 |
Initial Flare Symptoms Resulting from Use of LHRH Agonist in Metastatic Prostate Cancer: Systematic Review and Economic EvaluationPoon, Yeesha 03 January 2011 (has links)
Background
LHRH agonists decrease tumour size/activity by suppressing testosterone in prostate cancer; however, initial injection causes testosterone surge that triggers flare symptoms. Anti-androgen given with agonist may reduce/avoid flare symptoms.
When LHRH antagonist/blocker is introduced, testosterone suppression is immediate, but there is uncertainty about significance of flare symptoms without anti-androgen.
Objective
Systematic review compared significance of flare symptoms avoided and cost utility analysis using modelling comparing incremental value of blocker (degarelix) OR agonist (goserelin)+anti-androgen (bicalutamide) VERSUS agonist alone in prostate cancer patients.
Outcome
Incremental cost/QALY of bone pain as flare symptom between treatments
Results
Thirteen studies were reviewed. There was no standard definition for flare symptoms or data on LHRH antagonist versus other treatments on flare. From societal perspective, goserelin+bicalutamide was dominated over goserelin alone and similarly, from public perspective, goserelin+bicalutamide had favourable cost effectiveness profile against goserelin.
Conclusion
With bone pain as clinical endpoint, LHRH agonist+anti-androgen had favourable cost-effectiveness profile compared to goserelin.
|
Page generated in 0.042 seconds